
Dutasteride (0.5mg) + Tamsulosin (0.4mg)
Active composition
+1 more active ingredient
Dutasteride inhibits both type I and type II 5-alpha reductase enzymes, decreasing DHT levels and prostate growth.
Tamsulosin selectively antagonizes alpha-1 adrenergic receptors in the prostate and bladder neck, leading to smooth muscle relaxation and improved urine flow.
Medical applications
Geritam D Tablet ER is a combination pharmaceutical formulation containing Tamsulosin 0.4 mg and Dutasteride 0.5 mg, indicated for the management of benign prostatic hyperplasia (BPH). Tamsulosin, an alpha-1 adrenergic receptor antagonist, facilitates the relaxation of smooth muscle in the bladder neck and prostate, thereby improving urine flow and reducing symptoms associated with BPH such as urinary frequency, urgency, and nocturia. Dutasteride, a 5-alpha-reductase inhibitor, acts by blocking the conversion of testosterone to dihydrotestosterone (DHT), a hormone responsible for prostate enlargement. The extended-release (ER) formulation ensures a sustained therapeutic effect, enhancing patient compliance through once-daily dosing. Geritam D Tablet ER is particularly beneficial in patients with moderate to severe symptoms of BPH and those at risk of disease progression. Clinical studies have demonstrated its efficacy in reducing prostate volume, improving urinary flow rates, and decreasing the risk of acute urinary retention and the need for surgical intervention. Common adverse effects may include dizziness, headache, ejaculation disorders, and potential hypersensitivity reactions. Due to its pharmacodynamic profile, caution is advised in patients with hepatic impairment or a history of hypersensitivity to either component. Regular monitoring and consultation with a healthcare professional are recommended to optimize therapeutic outcomes and minimize risks.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Geritam D Tablet ER during pregnancy is not available. Please consult your doctor.
High Risk
Information regarding the use of Geritam D Tablet ER during breastfeeding is not available. Please consult your doctor.
Medical Advice
There is limited information available on the use of Geritam D Tablet ER in patients with kidney disease. Please consult your doctor.
Exercise Caution
Geritam D Tablet ER may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Geritam D Tablet ER should be used with caution in patients with liver disease. Dose adjustment of Geritam D Tablet ER may be needed. Please consult your doctor. Use of Geritam D Tablet ER is not recommended in patients with severe liver disease.
Regular Checkup
0 reviews for Geritam D Tablet ER

Tamsulosin (0.4mg) + Dutasteride (0.5mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Dutasteride inhibits both type I and type II 5-alpha reductase enzymes, decreasing DHT levels and prostate growth.
Tamsulosin selectively antagonizes alpha-1 adrenergic receptors in the prostate and bladder neck, leading to smooth muscle relaxation and improved urine flow.
Medical applications
Geritam D Tablet ER is a combination pharmaceutical formulation containing Tamsulosin 0.4 mg and Dutasteride 0.5 mg, indicated for the management of benign prostatic hyperplasia (BPH). Tamsulosin, an alpha-1 adrenergic receptor antagonist, facilitates the relaxation of smooth muscle in the bladder neck and prostate, thereby improving urine flow and reducing symptoms associated with BPH such as urinary frequency, urgency, and nocturia. Dutasteride, a 5-alpha-reductase inhibitor, acts by blocking the conversion of testosterone to dihydrotestosterone (DHT), a hormone responsible for prostate enlargement. The extended-release (ER) formulation ensures a sustained therapeutic effect, enhancing patient compliance through once-daily dosing. Geritam D Tablet ER is particularly beneficial in patients with moderate to severe symptoms of BPH and those at risk of disease progression. Clinical studies have demonstrated its efficacy in reducing prostate volume, improving urinary flow rates, and decreasing the risk of acute urinary retention and the need for surgical intervention. Common adverse effects may include dizziness, headache, ejaculation disorders, and potential hypersensitivity reactions. Due to its pharmacodynamic profile, caution is advised in patients with hepatic impairment or a history of hypersensitivity to either component. Regular monitoring and consultation with a healthcare professional are recommended to optimize therapeutic outcomes and minimize risks.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Geritam D Tablet ER during pregnancy is not available. Please consult your doctor.
High Risk
Information regarding the use of Geritam D Tablet ER during breastfeeding is not available. Please consult your doctor.
Medical Advice
There is limited information available on the use of Geritam D Tablet ER in patients with kidney disease. Please consult your doctor.
Exercise Caution
Geritam D Tablet ER may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Geritam D Tablet ER should be used with caution in patients with liver disease. Dose adjustment of Geritam D Tablet ER may be needed. Please consult your doctor. Use of Geritam D Tablet ER is not recommended in patients with severe liver disease.
Regular Checkup
0 reviews for Geritam D Tablet ER















